2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 077

Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup
Abstract Number: 103

Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada
Abstract Number: 135

Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
Abstract Number: 090

Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease
Abstract Number: 191

Utilization of Telemedicine in Pediatric Rheumatologic Care
Abstract Number: 101

Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond
Abstract Number: 085

Vitamin C Deficiency: An Under-Recognized Cause for Pediatric Limb Pain
Abstract Number: 001

WITHDRAWN
Abstract Number: 002

WITHDRAWN
Abstract Number: 111

WITHDRAWN
Abstract Number: 112

WITHDRAWN
Abstract Number: 142

WITHDRAWN
Abstract Number: 083

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].